Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Healthlead PCLBKK:HL 68 3-Year ROIIC % is -11.95 as of Dec. 2025. GuruFocus rates BKK:HL with a GF Score™ of 68/100 and a GF Value™ of ฿10.95 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 620 Healthcare Providers & Services companies, Healthlead PCL ranks worse than 71.45% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Healthlead PCL's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -11.95%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Healthlead PCL's 3-Year ROIIC % or its related term are showing as below:
BKK:HL's 3-Year ROIIC % is ranked worse than 71.45% of 620
companies
in the Healthcare Providers & Services industry
Industry Median: 3.48
vs BKK:HL: -11.95
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Healthlead PCL 3-Year ROIIC % Related Terms
Healthlead PCL 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Healthlead PCL's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Healthlead PCL's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healthlead PCL 3-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Healthlead PCL's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Healthlead PCL's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Healthlead PCL (BKK:HL) has a 3-Year ROIIC % of -11.95 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Healthlead PCL and its competitors. According to the industry distribution chart, Healthlead PCL ranks #443 out of 620 companies in the Healthcare Providers & Services industry, placing it in the top 71.5%.
Is Healthlead PCL's 3-Year ROIIC % too high?
Healthlead PCL's current 3-Year ROIIC % is -11.95. Based on the distribution chart, Healthlead PCL ranks #443 out of 620 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Healthlead PCL has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Healthlead PCL's 3-Year ROIIC % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Healthlead PCL ranks #443 out of 620 companies for 3-Year ROIIC %. This places Healthlead PCL in the lower half of its industry. The industry median 3-Year ROIIC % is 3.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Healthcare Providers & Services company?
The median 3-Year ROIIC % among Healthcare Providers & Services companies is 3.48, based on 620 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Healthlead PCL and its competitors. For the Healthcare Providers & Services industry, the median 3-Year ROIIC % is 3.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Healthlead PCL's current 3-Year ROIIC % is -11.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healthlead PCL stock overvalued right now?
Based on GuruFocus' analysis, Healthlead PCL (BKK:HL) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿10.95, compared to a current price of ฿5.65 — trading 48.4% below its estimated fair value. The current 3-Year ROIIC % is -11.95. Healthlead PCL's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Healthlead PCL (BKK:HL), the current 3-Year ROIIC % is -11.95 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healthlead PCL (BKK:HL) Overvalued in 2026?
Based on GuruFocus' analysis, Healthlead PCL stock appears to be undervalued.
The current stock price of ฿5.65 is trading 48.4% below its estimated GF Value™ of ฿10.95.
GuruFocus considers Healthlead PCL to be Significantly Undervalued.
Key valuation signals for BKK:HL:
3-Year ROIIC %: -11.95
GF Value™: ฿10.95 vs. price of ฿5.65 (48.4% below fair value)
No single metric tells the full story. See the BKK:HL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healthlead PCL is a holding company. Along with its subsidiaries, it operates a pharmacy business under iCare, Pharmax, vitaminclub, and Super Drug brands, distributing medicines, medical supplies, cosmeceuticals, dietary supplements, medical devices, and other healthcare products. Additionally, it is involved in co-inventing and co-developing healthcare products in collaboration with external research teams and contract manufacturers, producing and distributing its own branded products. Geographically, the group operates only in Thailand.
68GF Score
Get the complete analysis for BKK:HL
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:HL has been successfully added to your 
